Establishment and comparison of 2 mouse models of kainic acid induced epilepsy
Neuroscience|更新时间:2026-01-09
|
Establishment and comparison of 2 mouse models of kainic acid induced epilepsy
Journal of Army Medical UniversityVol. 46, Issue 7, Pages: 661-669(2024)
作者机构:
1.400037 重庆,陆军军医大学(第三军医大学)第二附属医院神经内科
2.637000 四川 南充,川北医学院附属医院神经内科
3.400037 重庆,陆军军医大学(第三军医大学)第二附属医院临床医学研究中心
作者简介:
基金信息:
the General Program of National Natural Science Foundation of China(81971221);the General Program of Natural Science Foundation of Chongqing(cstc2021jcyj-msxm3511)
Can TENG, Meiling YU, Guohui JIANG, et al. Establishment and comparison of 2 mouse models of kainic acid induced epilepsy[J]. Journal of Army Medical University, 2024, 46(7): 661-669.
DOI:
Can TENG, Meiling YU, Guohui JIANG, et al. Establishment and comparison of 2 mouse models of kainic acid induced epilepsy[J]. Journal of Army Medical University, 2024, 46(7): 661-669. DOI: 10.16016/j.2097-0927.202312098.
Establishment and comparison of 2 mouse models of kainic acid induced epilepsy
To investigate and analyze the behavioral and pathological differences in early-stage mouse models of epilepsy established by 2 different administration routes for kainic acid (KA)
intracerebroventricular (ICV) injection and intraperitoneal (IP) injection.
Methods
2
A total of 100 male C57BL/6N wild-type (WT) mice (20~22 g) were randomly divided into ICV+ normal saline (NS)control group(
n
=10)
ICV+KA model group(
n
=40)
IP+NS control group(
n
=10) and IP+KA model group (
n
=40). The ICV+KA model group was given 600 nL of KA (0.5 mg/mL)
via
ICV injection
and the IP+KA model group was injected with different dose of KA (25 mg/kg). Two control groups were administered equal volumes of NS
via
corresponding routes. After 3 d of modeling
the evaluation of behavioristics
molecular biology (including Western blotting)
and neuropathological assessments (including FJB staining
TUNEL staining and immunofluorescence staining) were performed.
Results
2
No epileptic seizures were observed in both 2 control groups
while exhibited seizures were observed in both model gro
ups. The mortality rates of the IP+KA group and the ICV+KA group were 47.50% and 65.00% respectively
while the success rates of modeling were 80.00% and 60.00% respectively. Compared with the IP+KA group
the ICV+KA group showed a significant increase in success rate and a significant reduction in mortality rate. FJB and TUNEL staining results showed that
compared with the IP+KA group
the severity of neurodegeneration and apoptotic changes in the hippocampus of the ICV+KA group were more significant (
P
<
0.05). Compared with the IP+KA group
there was also a significant difference in the expression of apoptotic proteins in the hippocampus of the ICV+KA group (
P
<
0.05). Immunofluorescence results showed that the astrocytes and microglia in the hippocampus and cortex of the ICV+KA and IP+KA groups were significantly activated compared with the control groups (
P
<
0.05)
but the activation of glial cells in the hippocampus and cortex of the ICV+KA group was stronger than that of the IP+KA model group (
P
<
0.05) and the activation levels in the ICV+KA group were higher than in the IP+KA model group (
P
<
0.01). Moreover
expression levels of GFAP and Iba-1 proteins in the hippocampus and cortex were higher in the ICV+KA group than the IP+KA group (
P
<
0.05).
Conclusion
2
Two routes of KA administration are effective in construct epilepsy models. The mice with ICV administration route show a higher success rate and lower mortality rate
and more significant neuropathological damage and glial cell activation.
关键词
Keywords
references
FISHER R S, ACEVEDO C, ARZIMANOGLOU A, et al . ILAE Official Report: a practical clinical definition of epilepsy[J ] . Epilepsia, 2014, 55(4): 475-482. DOI: 10.1111/epi.12550.
THIJS R D, SURGES R, O'BRIEN T J, et al . Epilepsy in adults[J ] . Lancet, 2019, 393(10172): 689-701. DOI: 10.1016/S0140-6736(18)32596-0.
NELIGAN A, HAUSER W A, SANDER J W. The epidemiology of the epilepsies[J]. Handb Clin Neurol, 2012, 107: 113-133. DOI: 10.1016/B978-0-444-52898-8.00006-9.
KWAN P, BRODIE M J. Early identification of refractory epilepsy[J]. N Engl J Med, 2000, 342(5): 314-319. DOI: 10.1056/NEJM200002033420503.
KALILANI L, SUN X Z, PELGRIMS B, et al . The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis[J ] . Epilepsia, 2018, 59(1 2): 2179-2193. DOI: 10.1111/epi.14596.
WANG F X, YANG X L, MA Y S, et al . TRIF contributes to epileptogenesis in temporal lobe epilepsy during TLR4 activation[J ] . Brain Behav Immun, 2018, 67: 65-76. DOI: 10.1016/j.bbi.2017.07.157.
KEISER M S, CHEN Y H, DAVIDSON B L. Techniques for intracranial stereotaxic injections of adeno-associated viral vectors in adult mice[J]. Curr Protoc Mouse Biol, 2018, 8(4): e57. DOI: 10.1002/cpmo.57.
PIJET B, KONOPKA A, REJMAK E, et al . The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus[J ] . Sci Rep, 2020, 10: 21314. DOI: 10.1038/s41598-020-78341-y.
FERRARO T N, GOLDEN G T, SMITH G G, et al . Differential susceptibility to seizures induced by systemic kainic acid treatment in mature DBA/2J and C57BLl6J mice[J ] . Epilepsia, 1995, 36(3): 301-307. DOI: 10.1111/j.1528-1157.1995.tb00999.x.
BERGEY G K, MORRELL M J, MIZRAHI E M, et al . Long-term treatment with responsive brain stimulation in adults with refractory partial seizures[J ] . Neurology, 2015, 84(8): 810-817. D OI: 10.1212/wnl.0000000000001280.
DU K, HE M, ZHAO D Y, et al . Mechanism of cell death pathways in status epilepticus and related therapeutic agents[J ] . Biomed Pharmacother, 2022, 149: 112875. DOI: 10.1016/j.biopha.2022.112875.
SOKOLOVA T V, ZABRODSKAYA Y M, LITOVCHENKO A V, et al . Relationship between neuroglial apoptosis and neuroinflammation in the epileptic focus of the brain and in the blood of patients with drug-resistant epilepsy[J ] . Int J Mol Sci, 2022, 23(20): 12561. DOI: 10.3390/ijms232012561.
NABBOUT R, KUCHENBUCH M. Impact of predictive, preventive and precision medicine strategies in epilepsy[J]. Nat Rev Neurol, 2020, 16(12): 674-688. DOI: 10.1038/s41582-020-0409-4.
UPAGANLAWAR A B, WANKHEDE N L, KALE M B, et al . Interweaving epilepsy and neurodegeneration: vitamin E as a treatment approach[J ] . Biomed Pharmacother, 2021, 143: 112146. DOI: 10.1016/j.biopha.2021.112146.
SCHMUED L C, HOPKINS K J. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration[J]. Brain Res, 2000, 874(2): 123-130. DOI: 10.1016/S0006-8993(00)02513-0.
VEZZANI A, RAVIZZA T, BEDNER P, et al . Astrocytes in the initiation and progression of epilepsy[J ] . Nat Rev Neurol, 2022, 18(12): 707-722. DOI: 10.1038/s41582-022-00727-5.
YU C, DENG X J, XU D. Microglia in epilepsy[J]. Neurobiol Dis, 2023, 185: 106249. DOI: 10.1016/j.nbd.2023.106249.
PURNELL B S, ALVES M, BOISON D. Astrocyte-neuron circuits in epilepsy[J]. Neurobiol Dis, 2023, 179: 106058. DOI: 10.1016/j.nbd.2023.106058.
VEZZANI A, DI SAPIA R, KEBEDE V, et al . Neuroimmunology of status epilepticus[J ] . Epilepsy Behav, 2023, 140: 109095. DOI: 10.1016/j.yebeh.2023.109095.
CHEN Y, NAGIB M M, YASMEN N, et al . Neuroinflammatory mediators in acquired epilepsy: an update[J ] . Inflamm Res, 2023, 72(4): 683-701. DOI: 10.1007/s00011-023-01700-8.